Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence. (PubMed, Kidney Int Rep) - Oct 8, 2026 - "Selective APRIL inhibitors (sibeprenlimab, zigakibart) and dual BAFF-APRIL inhibitors (atacicept, povetacicept, and telitacicept) reduce Gd-IgA1, hematuria, proteinuria and prevent estimated glomerular filtration rate (eGFR) decline. Collectively, these findings position the BAFF and APRIL axis as a central therapeutic node in IgAN, and support biomarker-guided, mechanism-based treatment strategies aimed at long-term disease modification. This review summarizes translational and clinical data on the BAFF and APRIL axis in IgAN, including evidence from recently published clinical trials."
IO biomarker • Journal • Review • Glomerulonephritis • IgA Nephropathy • Oncology • Renal Disease • TNFA
|
|
Arun Rajasekaran; George Vasquez-Rios; Kirk N Campbell; Luis Sanchez Russo; Paolo Cravedi; Steven G Coca
|